JPRN-UMIN000004959已完成1 期
Cancer vaccine therapy with HLA-A24 restricted epitope peptide cocktail for patients with advanced metastatic colorectal cancer. Phase I/II clinical trial. - Peptide vaccine therapy for patients with advanced metastatic colorectal cancer.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Pregnant Lactation Prognosis >= 3 months Active infectious disease Systemic use of steroid hormones or immunosuppressive drugs. Others (Doctors judges)
研究者
相似试验
招募中
1 期
Cancer vaccine therapy with HLA-A24 restricted epitope peptide cocktail for patients with advanced metastatic colorectal cancer. Phase I/II clinical trial.Advanced metastatic colorectal cancersJPRN-UMIN000006312Kinki University School of Medicine Department of Surgery30
已完成
1 期
Cancer specific vaccine therapy using HLA-A24 restricted epitope-peptide for patients with advanced metastatic colorectal cancer.PhaseI/II clinical trial.colorectal cancerJPRN-UMIN000004994Hokkaido Cancer Center30
已完成
1 期
Cancer therapy with vaccination using HLA-A24-restricted peptide from RNF43:a phase I study in patients with unresectable colorectal cancerunresectable colorectal cancerJPRN-UMIN000000702Institute of Medical Science, University of Tokyo6
已完成
1 期
Cancer therapy with vaccination using HLA-A24-restricted peptide from TOMM34:a phase I study in patients with unresectable colorectal cancerunresectable colorectal cancerJPRN-UMIN000000782Institute of Medical Science, University of Tokyo6
已完成
1 期
Cancer therapy with vaccination using HLA-A24-restricted peptide from URLC10:a phase I study in patient with unresectable esophageal cancerunresectable esophageal cancerJPRN-UMIN000000955Institute of Medical Science The University of Tokyo6